Print

Active Biotech in brief

Active Biotech is a company with focus on the development of pharmaceutical products within medical areas where the immune defense is of significant importance. The project portfolio comprises projects in development for neurodegenerative diseases, autoimmunity and cancer. Active Biotech operations are primarily focused on the ongoing partnerships within the laquinimod and ANYARA projects. In addition, activities are ongoing to find strategic and competent partners to secure the continued development of tasquinimod, paquinomod and the SILC programs.

Laquinimod

Laquinimod is a once-daily oral, investigational, CNS-active immunomodulatory compound with a novel mechanism of action being developed for the treatment of relapsing-remitting MS (RRMS), primary progressive MS (PPMS) and Huntington's disease (HD).

Active Biotech has an agreement with the pharmaceutical company Teva Pharmaceutical Industries Ltd. (NYSE: TEVA) for the worldwide development and commercialization of laquinimod.

ANYARA

ANYARA is a TTS (Tumor Targeting Superantigen) substance, a protein drug that makes the treatment of cancer tumor-specific by local immune activation in the tumor area. The development of ANYARA has primarily been focused on renal cell cancer, but the compound has also demonstrated favorable clinical results in connection with the treatment of, non-small cell lung cancer and pancreatic cancer.

Since October 2016, Active Biotech has an agreement with NeoTX therapeutics Ltd, an Israeli immuno-oncology company.  NeoTX is responsible for the worldwide development and commercialization of the ANYARA project.